Ferroptosis of Pacemaker Cells in COVID-19.
Ferroptosis of Pacemaker Cells in COVID-19.
复制标题
COVID-19 中起搏细胞的铁死亡。
DOI：
10.1161/circresaha.122.320951
复制
发表时间：
2022
影响因子：
20.1
通讯作者：
Wu,JosephC
中科院分区：
文献类型：
--
作者：
Nishiga,Masataka;Jahng,JamesWS;Wu,JosephC
COVID-19（2019冠状病毒病）可导致各种心血管并发症，包括心肌损伤、血管损伤和血栓栓塞1。心律失常是COVID-19最常见的心脏表现之一。尽管在COVID-19患者的急性期经常看到心动过速（如房颤），但在COVID-192的急性期也报告了心动过缓。最近，COVID-19的长期后遗症（称为长期COVID）已在包括心脏在内的各种器官中报告3 -5。在急性期后，一些COVID-19幸存者因心率失调、房颤和体位性直立性心动过速综合征而出现心悸。
COVID-19 (coronavirus disease 2019) can lead to various cardiovascular complications, including myocardial injury, vascular injury, and thromboembolism1. Arrhythmias are one of the most common cardiac manifestations in COVID-19. Although tachycardias such as atrial fibrillation are often seen in the acute phase of patients with COVID-19, bradycardias are also reported in the acute phase of COVID-192. More recently, longterm sequelae of COVID-19, known as long-COVID, have been reported in various organs including the heart3–5. In the postacute phase, some COVID-19 survivors suffer from palpitations due to dysregulated heart rates, atrial fibrillation, and postural orthostatic tachycardia syndrome.